Trutect gives veterinarians a new tool against canine parvo

Canine parvovirus finally has a targeted treatment option, and the category is moving fast. Elanco’s canine parvovirus monoclonal antibody, first launched under conditional USDA approval in May 2023, received full USDA approval in December 2025 and is now marketed as Trutect. The product is positioned as the first USDA-approved treatment for canine parvovirus beyond supportive care, and its label expansion in June 2025 also added passive immunity for exposed puppies, giving veterinarians both a therapeutic and a preventive-use option in certain cases. Elanco says real-world use showed a 93% survival rate among treated puppies and an average reduction of 1.87 hospital days. (elanco.com)

Why it matters: For veterinary teams, this changes the parvo conversation from supportive care alone to supportive care plus a targeted biologic. That could matter most in ER, GP, and shelter settings where parvo drives isolation burden, staffing strain, treatment costs, and difficult conversations with pet parents. Independent clinical commentary has also emphasized that the monoclonal antibody appears to shorten hospitalization and clinical signs, though it should be used alongside standard supportive care, not as a replacement. A shelter-based retrospective study presented at ISCAID 2024 found shorter hospitalization and faster negative SNAP testing with CPV monoclonal antibody plus standard of care, while survival was similar to standard care in that specific shelter cohort. (assets.elanco.com)

What to watch: Watch for more peer-reviewed field data, broader clinic uptake, and how practices use the passive-immunity indication during shelter or community outbreaks. (elanco.com)